Adam S. Grossman Buys 485,000 Shares of ADMA Biologics Inc (ADMA) Stock

ADMA Biologics Inc (NASDAQ:ADMA) insider Adam S. Grossman bought 485,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The stock was purchased at an average price of $2.15 per share, with a total value of $1,042,750.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

ADMA Biologics Inc (NASDAQ ADMA) traded down $0.08 on Monday, hitting $2.32. The stock had a trading volume of 341,800 shares, compared to its average volume of 50,811. The company has a debt-to-equity ratio of 2.26, a quick ratio of 1.35 and a current ratio of 2.36. ADMA Biologics Inc has a 52-week low of $2.01 and a 52-week high of $6.88.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Friday, August 11th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.29). ADMA Biologics had a negative net margin of 35.00% and a negative return on equity of 76.26%. The business had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $3.52 million. equities analysts anticipate that ADMA Biologics Inc will post -2.25 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Adam S. Grossman Buys 485,000 Shares of ADMA Biologics Inc (ADMA) Stock” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/11/13/adam-s-grossman-buys-485000-shares-of-adma-biologics-inc-adma-stock.html.

Separately, ValuEngine downgraded ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply